Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 32
Filtrar
1.
J Assist Reprod Genet ; 40(12): 2819-2825, 2023 Dec.
Artículo en Inglés | MEDLINE | ID: mdl-37796419

RESUMEN

Fertility preservation in pregnant women recently diagnosed with cancer can be a challenge. Raised levels of human chorionic gonadotropin (Beta-hCG) and progesterone in this population of patients may pose a problem for the prompt initiation of controlled ovarian stimulation (COS) due to a potential negative feedback of these hormones on folliculogenesis; however, it is not feasible to wait for negativization of serum beta-hCG levels before starting controlled ovarian stimulation. In literature, very few cases have been reported regarding the preservation of fertility in pregnant women recently diagnosed with cancer. We performed an extended revision of the literature to evaluate the current knowledge of the management of fertility preservation in women with cancer and we examined two cases closely. The first case study involved a cancer patient who underwent surgical abortion at 6.5 weeks of gestation followed by administration of mifepristone to detach any minimal residual trophoblast and consequently to decrease serum beta-hCG and progesterone levels before starting COS. In the second case study, the cancer patient underwent surgical abortion at 7.1 weeks of gestation and simultaneous unilateral oophorectomy for ovarian tissue cryopreservation due to a limited time for COS. By analyzing the results of these studies, it could be hypothesized that mifepristone administration may favor the decrease of serum beta-hCG and progesterone levels in order to permit rapid initiation of COS. In cases where COS is not feasible, ovarian tissue cryopreservation should be considered as an alternative fertility preservation technique.


Asunto(s)
Preservación de la Fertilidad , Neoplasias , Humanos , Femenino , Embarazo , Preservación de la Fertilidad/métodos , Progesterona , Primer Trimestre del Embarazo , Mifepristona/uso terapéutico , Criopreservación/métodos , Neoplasias/complicaciones , Neoplasias/tratamiento farmacológico , Inducción de la Ovulación/métodos
3.
Artículo en Inglés | MEDLINE | ID: mdl-35532249

RESUMEN

OBJECTIVE: Hyperandrogenic skin disorders, such as hirsutism, acne and alopecia, affect approximately 10-20% of women of reproductive age, reducing quality of life and causing psychological impairment. Spironolactone is a commonly used antiandrogen, especially in women who are not sexually active or have contraindications to hormonal contraceptives. The aim of this study was to evaluate the effects of spironolactone, especially after its withdrawal, in patients with hyperandrogenic skin disorders. METHODS: Retrospective analysis of 63 women with hyperandrogenic skin symptoms due to polycystic ovary syndrome (PCOS), treated with spironolactone for at least 6 months as first-line treatment. RESULTS: After a mean time of treatment of 25.7 months, all patients reported a significant improvement in hyperandrogenic skin disorders; only 5 patients were dissatisfied and required the addition of an oral contraceptive. The therapy was well tolerated and the most frequent side-effect was intermestrual bleeding in 68.2% of cases, affecting mainly classic PCOS phenotype. Thirthyeight patients showed prolonged effects 33.7 months after spironolactone withdrawal, whereas 20 relapsed 17.5 months after discontinuation. No significant difference in clinical and biochemical parameters was observed between these two groups both at baseline and after spironolactone treatment. Ovulatory PCOS patients were treated for a shorter time and reported earlier relapse than classic PCOS patients. CONCLUSION: Spironolactone is an effective and safe treatment for hyperandrogenic skin disorders, showing long-lasting effects even several months after its discontinuation.


Asunto(s)
Síndrome del Ovario Poliquístico , Espironolactona , Humanos , Femenino , Espironolactona/efectos adversos , Estudios Retrospectivos , Calidad de Vida , Recurrencia Local de Neoplasia/complicaciones , Recurrencia Local de Neoplasia/tratamiento farmacológico , Hirsutismo/diagnóstico , Hirsutismo/tratamiento farmacológico , Hirsutismo/etiología , Síndrome del Ovario Poliquístico/tratamiento farmacológico , Síndrome del Ovario Poliquístico/diagnóstico
4.
J Assist Reprod Genet ; 39(1): 219-226, 2022 Jan.
Artículo en Inglés | MEDLINE | ID: mdl-34791588

RESUMEN

PURPOSE: The current gold standard for chronic endometritis (CE) diagnosis is immunohistochemistry (IHC) for CD-138. However, IHC for CD-138 is not exempt from diagnostic limitations. The aim of our study was to evaluate the reliability and accuracy of MUM-1 IHC, as compared with CD-138. METHODS: This is a multi-centre, retrospective, observational study, which included three tertiary hysteroscopic centres in university teaching hospitals. One hundred ninety-three consecutive women of reproductive age were referred to our hysteroscopy services due to infertility, recurrent miscarriage, abnormal uterine bleeding, endometrial polyps or myomas. All women underwent hysteroscopy plus endometrial biopsy. Endometrial samples were analysed through histology, CD138 and MUM-1 IHC. The primary outcome was to evaluate the diagnostic accuracy of MUM-1 IHC for CE, as compared with CD-138 IHC. RESULTS: Sensitivity and specificity of CD-138 and MUM-1 IHC were respectively 89.13%, 79.59% versus 93.48% and 85.03%. The overall diagnostic accuracy of MUM-1 and CD-138 IHC were similar (AUC = 0.893 vs AUC = 0.844). The intercorrelation coefficient for single measurements was high between the two techniques (ICC = 0.831, 0.761-0.881 95%CI). However, among CE positive women, MUM-1 allowed the identification of higher number of plasma cells/hpf than CD-138 (6.50 [SD 4.80] vs 5.05 [SD 3.37]; p = 0.017). Additionally, MUM-1 showed a higher inter-observer agreement as compared to CD-138. CONCLUSION: IHC for MUM-1 and CD-138 showed a similar accuracy for detecting endometrial stromal plasma cells. Notably, MUM-1 showed higher reliability in the paired comparison of the individual samples than CD-138. Thus, MUM-1 may represent a novel, promising add-on technique for the diagnosis of CE.


Asunto(s)
Endometritis/diagnóstico , Inmunohistoquímica/métodos , Factores Reguladores del Interferón/inmunología , Adulto , Biomarcadores/análisis , Biomarcadores/sangre , Endometritis/sangre , Femenino , Humanos , Inmunohistoquímica/estadística & datos numéricos , Reproducibilidad de los Resultados , Estudios Retrospectivos , España , Sindecano-1/análisis
5.
Int J Mol Sci ; 22(21)2021 Oct 31.
Artículo en Inglés | MEDLINE | ID: mdl-34769256

RESUMEN

Endometrial cancer (EC) is a deleterious condition which strongly affects a woman's quality of life. Although aggressive interventions should be considered to treat high-grade EC, a conservative approach should be taken into consideration for women wishing to conceive. In this scenario, we present an overview about the EC fertility-sparing approach state of art. Type I EC at low stage is the only histological type which can be addressed with a fertility-sparing approach. Moreover, no myometrium and/or adnexal invasion should be seen, and lymph-vascular space should not be involved. Regarding the pharmaceutical target, progestins, in particular medroxyprogesterone acetate (MPA) or megestrol acetate (MA), are the most employed agent in conservative treatment of early-stage EC. The metformin usage and hysteroscopic assessment is still under debate, despite promising results. Particularly strict and imperious attention should be given to the follow-up and psychological wellbeing of women, especially because of the double detrimental impairment: both EC and EC-related infertility consequences.


Asunto(s)
Neoplasias Endometriales/tratamiento farmacológico , Preservación de la Fertilidad , Fertilidad/efectos de los fármacos , Acetato de Medroxiprogesterona/uso terapéutico , Progestinas/uso terapéutico , Calidad de Vida , Adulto , Neoplasias Endometriales/metabolismo , Femenino , Humanos , Miometrio/metabolismo , Estadificación de Neoplasias
6.
J Gynecol Obstet Hum Reprod ; 50(4): 101815, 2021 Apr.
Artículo en Inglés | MEDLINE | ID: mdl-32562778

RESUMEN

Aim of this report is to alert clinicians about the potential significant sequelae of administering depot gonadotropin-releasing hormone agonists (GnRHa) shortly after oocytes cryopreservation. In our case report, a 28-year-old nulligravid Caucasian woman diagnosed with breast cancer underwent controlled ovarian stimulation-oocyte cryopreservation before chemotherapy. The oocyte retrieval was performed without complications and the woman was discharged after five hours. Three days later, the patient self-injected depot-GnRHa as chemoprotective agent, as indicated by the oncologist. The next day, the patient referred to the emergency room and she was diagnosed with ovarian hyperstimulation syndrome (OHSS) and required inpatient care. As a consequence, the start of the chemotherapy was delayed by two weeks. In conclusion, chemoprotection with depot-GnRHa after oocyte/embryo cryopreservation is not exempt from risks. The timing for depot-GnRHa administration should be established by the agreement between oncologist and gynecologist in order to avoid the risk of OHSS.


Asunto(s)
Criopreservación , Crioprotectores/efectos adversos , Hormona Liberadora de Gonadotropina/agonistas , Oocitos , Síndrome de Hiperestimulación Ovárica/inducido químicamente , Adulto , Anticoagulantes/administración & dosificación , Antineoplásicos Hormonales/administración & dosificación , Ascitis/diagnóstico por imagen , Crioprotectores/administración & dosificación , Esquema de Medicación , Enoxaparina/administración & dosificación , Femenino , Hormona Folículo Estimulante Humana/administración & dosificación , Humanos , Letrozol/administración & dosificación , Recuperación del Oocito/métodos , Inducción de la Ovulación/métodos , Proteínas Recombinantes/administración & dosificación , Autoadministración , Neoplasias de la Mama Triple Negativas/sangre , Neoplasias de la Mama Triple Negativas/tratamiento farmacológico , Pamoato de Triptorelina/administración & dosificación
8.
Obstet Gynecol Surv ; 75(7): 431-444, 2020 Jul.
Artículo en Inglés | MEDLINE | ID: mdl-32735685

RESUMEN

IMPORTANCE: To date, a comprehensive review on the safety and effectiveness of hysteroscopic metroplasty for T-shaped uterus is still missing. OBJECTIVE: To provide a robust synthesis of the available studies investigating reproductive outcomes after hysteroscopic metroplasty for T-shaped uterus. EVIDENCE ACQUISITION: We performed a systematic review and meta-analysis (CRD42019143291), using the proportion method with 95% confidence interval (CI). Statistical heterogeneity was assessed by Higgins test (I2). RESULTS: We included 11 cohort studies embedding 937 women who underwent hysteroscopic metroplasty. After surgery, the pooled percentage of live birth was 44.54% (95% CI, 36.12%-53.12%; I2 = 46.22%) and 56.88% (95% CI, 46.48%-66.98%; I2 = 36.38%) in women with primary infertility and recurrent miscarriage, respectively. In women with recurrent miscarriage, the pooled proportion of miscarriage was 21.46% (95% CI, 15.09%-28.61%; I2 = 30.18%). The pooled clinical pregnancy proportion in women with primary infertility was 57.19% (95% CI, 43.83%-70.03%; I2 = 77.81%). The pooled rate of surgical complications was 0.65% (95% CI, 0.20%-1.33%; I2 = 11.44%). CONCLUSIONS: The hysteroscopic correction of T-shaped uteri was associated with high live birth rate and low miscarriage rate, both in case of primary infertility and recurrent miscarriage. RELEVANCE: Hysteroscopic metroplasty can be considered a safe and effective strategy to improve reproductive outcomes in case of T-shaped uterus.


Asunto(s)
Histeroscopía/métodos , Nacimiento Vivo/epidemiología , Anomalías Urogenitales/cirugía , Útero/anomalías , Aborto Espontáneo/epidemiología , Aborto Espontáneo/etiología , Adulto , Estudios de Cohortes , Femenino , Humanos , Infertilidad Femenina/epidemiología , Infertilidad Femenina/etiología , Complicaciones Posoperatorias/epidemiología , Anomalías Urogenitales/complicaciones , Anomalías Urogenitales/epidemiología , Útero/cirugía
9.
Int J Mol Sci ; 21(11)2020 Jun 05.
Artículo en Inglés | MEDLINE | ID: mdl-32517126

RESUMEN

Bicarbonate uptake is one of the early steps of capacitation, but the identification of proteins regulating anion fluxes remains elusive. The aim of this study is to investigate the role of sperm solute carrier 4 (SLC4) A1 (spAE1) in the capacitation process. The expression, location, and tyrosine-phosphorylation (Tyr-P) level of spAE1 were assessed. Thereby, it was found that 4,4'-Diisothiocyano-2,2'-stilbenedisulfonic acid (DIDS), an SLC4 family channel blocker, inhibited capacitation in a dose-dependent manner by decreasing acrosome reaction (ARC% 24.5 ± 3.3 vs 64.9 ± 4.3, p < 0.05) and increasing the percentage of not viable cells (NVC%), comparable to the inhibition by I-172, a cystic fibrosis transmembrane conductance regulator (CFTR) blocker (AR% 30.5 ± 4.4 and NVC% 18.6 ± 2.2). When used in combination, a synergistic inhibitory effect was observed with a remarkable increase of the percentage of NVC (45.3 ± 4.1, p < 0.001). spAE1 was identified in sperm membrane as a substrate for Tyr-protein kinases Lyn and Syk, which were identified as both soluble and membrane-bound pools. spAE1-Tyr-P level increased in the apical region of sperm under capacitating conditions and was negatively affected by I-172 or DIDS, and, to a far greater extent, by a combination of both. In conclusion, we demonstrated that spAE1 is expressed in sperm membranes and it is phosphorylated by Syk, but above all by Lyn on Tyr359, which are involved in sperm viability and capacitation.


Asunto(s)
Proteínas SLC4A/metabolismo , Capacitación Espermática/fisiología , Espermatozoides/fisiología , Tirosina/metabolismo , Reacción Acrosómica , Membrana Celular , Supervivencia Celular , Regulador de Conductancia de Transmembrana de Fibrosis Quística/genética , Regulador de Conductancia de Transmembrana de Fibrosis Quística/metabolismo , Humanos , Masculino , Fosforilación , Proteínas SLC4A/genética
10.
J Gynecol Obstet Hum Reprod ; 49(6): 101743, 2020 Jun.
Artículo en Inglés | MEDLINE | ID: mdl-32272168

RESUMEN

Infertility, defined as the absence of spontaneous conception after 12 months of unprotected sexual intercourses, is a major public health issue. It is estimated that up to 15% of couples suffer from infertility and that most of them will refer for counselling to infertility specialists. Concurrently, the demands for assisted reproduction techniques are steadily increasing worldwide. Endometrial scratching is an intentional endometrial injury offered to infertile women with the purpose of enhancing endometrial receptivity before intrauterine insemination or embryo transfer. Endometrial scratching is a simple and low-cost procedure that consists in a voluntary mechanical disruption of endometrial lining, with minor patients' discomfort. Whilst the data about the effectiveness of endometrial scratching in intrauterine insemination is low but coherent, there is a great deal of confusion about the role of endometrial scratching before IVF-embryo transfer cycles. The aim of this commentary is to summarize the current evidence about the effectiveness of endometrial scratching before assisted reproduction techniques and future perspectives about the use of this technique in infertile women.


Asunto(s)
Endometrio/lesiones , Endometrio/fisiología , Infertilidad Femenina/terapia , Técnicas Reproductivas Asistidas , Animales , Transferencia de Embrión , Femenino , Fertilización In Vitro/métodos , Humanos , Inseminación Artificial , Nacimiento Vivo , Embarazo , Índice de Embarazo
11.
Eur J Obstet Gynecol Reprod Biol ; 244: 154-162, 2020 Jan.
Artículo en Inglés | MEDLINE | ID: mdl-31786492

RESUMEN

To evaluate the effectiveness of delay start protocol in improving the success of in vitro fertilization (IVF) in poor responders according to Bologna's criteria. Only randomized controlled trial (RCT) of infertile women undergoing a single IVF/ICSI cycle with ovarian stimulation protocol based on daily injections with delay start protocol or a conventional antagonist protocol were included in this systematic review and meta-analysis. The review protocol was registered in PROSPERO before starting the data extraction (CRD42019128284). Primary outcome was clinical pregnancy rate. Ongoing pregnancy rate, miscarriage rate, number of oocytes, number of MII oocytes, stimulation length, gonadotropin amount and cancellation rate were considered as secondary outcomes. Four randomized controlled trials were included with a total number of 380 participants. 189 patients were included in the delayed start protocol and 191 were allocated to the comparison group. The results showed a significant higher clinical pregnancy rate (CPR) in patients allocated to the intervention. Data from all studies failed to detect a statistical difference between groups in terms of ongoing pregnancy rate (OPR), miscarriage rate (MR), Total-Oocyte, MII-Oocyte and Total-Embryos. Gonadotropin amount (GA) was significantly lower in the intervention group in comparison to controls, with no difference in stimulation length (SL) and cancelled cycle (CC). Delayed start GnRH-antagonist protocol may reduce GA and improve CPR in poor ovarian responder according to Bologna criteria.


Asunto(s)
Hormona Liberadora de Gonadotropina/antagonistas & inhibidores , Inducción de la Ovulación/métodos , Femenino , Humanos , Embarazo , Índice de Embarazo , Ensayos Clínicos Controlados Aleatorios como Asunto
12.
Artículo en Inglés | MEDLINE | ID: mdl-31507531

RESUMEN

Aldosterone is the main mineralocorticoid hormone, responsible of the regulation of fluid and electrolyte balance and blood pressure. It acts also as a pro-inflammatory factor responsible of an increased cardiovascular risk, independent from blood pressure values. After the discovery of mineralocorticoid receptor (MR) in mononuclear leukocytes, further studies supported its role in inflammatory and even autoimmune mechanisms underlying several diseases. In particular, recent studies reported a possible involvement of aldosterone in some gynecological conditions and diseases, characterized by inflammation, hypertension and increased cardio-metabolic risk, such as use of hormonal contraceptives, preeclampsia, polycystic ovary syndrome, uterine fibroids, and endometriosis. The aim of this mini-review is to report the possible involvement of aldosterone in all these gynecological conditions, suggesting different pathogenetic mechanisms and new target treatments of MR blockers for these diseases.

13.
Artículo en Inglés | MEDLINE | ID: mdl-31263452

RESUMEN

The most represented histotype of testicular cancer is the testicular germ-cell tumor (TGCT), both seminoma and non-seminoma. The pathogenesis of this cancer is poorly known. A possible causal relationship between viral infections and TGCTs was firstly evoked almost 40 years ago and is still a subject of debate. In the recent past, different authors have argued about a possible role of specific viruses in the development of TGCTs including human papillomavirus (HPV), Epstein-Barr virus (EBV), cytomegalovirus (CMV), Parvovirus B-19, and human immunodeficiency virus (HIV). The aim of this present review was to summarize, for each virus considered, the available evidence on the impact of viral infections on the risk of developing TGCTs. The review was reported following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. We included all observational studies reported in English evaluating the correlations between viral infections (HPV, CMV, EBV, Parvovirus B19, and HIV) and TGCTs. The methodological quality of studies included in the meta-analysis was evaluated using a modified version of the "Newcastle-Ottawa Scale." Meta-analyses were conducted using the "Generic inverse variance" method, where a pooled odds ratio (OR) was determined from the natural logarithm (LN) of the studies' individual OR [LN (OR)] and the 95% CI. A total of 20 studies (on 265,057 patients) were included in the review. Meta-analysis showed an association with TGCTs only for some of the explored viruses. In particular, no association was found for HPV, CMV, and Parvovirus B-19 infection (p = ns). Conversely, EBV and HIV infections were significantly associated with higher risk of developing TGCTs (OR 7.38, 95% CI 1.89-28.75, p = 0.004; OR 1.71, 95% CI 1.51-1.93, p < 0.00001). In conclusion, we found adequate evidence supporting an oncogenic effect of HIV and EBV on the human testis. Conversely, available data on HPV and TGCTs risk are conflicting and further studies are needed to draw firm conclusions. Finally, current evidence does not support an effect of CMV and Parvovirus B-19 on testicular carcinogenesis.

14.
Fertil Steril ; 111(4): 734-746.e2, 2019 04.
Artículo en Inglés | MEDLINE | ID: mdl-30683590

RESUMEN

OBJECTIVE: To investigate endometrial scratch injury (ESI) as an intervention to improve IVF outcome in women undergoing a first ET. DESIGN: Systematic review and meta-analysis. SETTING: Not applicable. PATIENT(S): Infertile women undergoing a first fresh/frozen embryo transfer. INTERVENTION(S): We included published and unpublished data from randomized controlled trials in which the intervention group received ESI and controls received placebo or no intervention. Pooled results were expressed as relative risk (RR) with 95% confidence interval (CI). The review protocol was registered in PROSPERO to start the data extraction (CRD42018087786). MAIN OUTCOME MEASURE(S): Ongoing pregnancy/live birth rate (OPR/LBR), clinical pregnancy rate (CPR), multiple pregnancy rate (MPR), miscarriage rate (MR), and ectopic pregnancy rate (EPR). RESULT(S): Seven studies were included (1,354 participants). We found a nonsignificant difference between groups in terms of OPR/LBR, CPR, MR, MPR, and EPR. Subgroup analysis found that ESI on the day of oocyte retrieval (achieved by a Novak curette) reduced OPR/LBR (RR 0.31, 95% CI 0.14-0.69) and CPR (RR 0.36, 95% CI 0.18-0.71), whereas ESI during the cycle preceding ET (performed through soft devices) had no effect on OPR/LBR and CPR. No difference in the impact of ESI was observed between fresh and frozen embryo transfer. CONCLUSION(S): Current evidence does not support performing ESI with the purpose of improving the success of a first ET attempt.


Asunto(s)
Implantación del Embrión/fisiología , Transferencia de Embrión/métodos , Endometrio/cirugía , Procedimientos Quirúrgicos Ginecológicos/métodos , Infertilidad Femenina/terapia , Ensayos Clínicos Controlados Aleatorios como Asunto/estadística & datos numéricos , Adulto , Transferencia de Embrión/estadística & datos numéricos , Endometrio/lesiones , Endometrio/patología , Femenino , Humanos , Infertilidad Femenina/epidemiología , Embarazo , Índice de Embarazo , Embarazo Ectópico/epidemiología , Embarazo Ectópico/etiología , Edición/estadística & datos numéricos , Resultado del Tratamiento
15.
Mar Drugs ; 16(11)2018 Nov 02.
Artículo en Inglés | MEDLINE | ID: mdl-30400141

RESUMEN

Astaxanthin (Asta), red pigment of the carotenoid family, is known for its anti-oxidant, anti-cancer, anti-diabetic, and anti-inflammatory properties. In this study, we evaluated the effects of Asta on isolated human sperm in the presence of human papillomavirus (HPV) 16 capsid protein, L1. Sperm, purified by gradient separation, were treated with HPV16-L1 in both a dose and time-dependent manner in the absence or presence of 30 min-Asta pre-incubation. Effects of HPV16-L1 alone after Asta pre-incubation were evaluated by rafts (CTB) and Lyn dislocation, Tyr-phosphorylation (Tyr-P) of the head, percentages of acrosome-reacted cells (ARC) and endogenous reactive oxygen species (ROS) generation. Sperm membranes were also analyzed for the HPV16-L1 content. Results show that HPV16-L1 drastically reduced membrane rearrangement with percentage of sperm showing head CTB and Lyn displacement decreasing from 72% to 15.8%, and from 63.1% to 13.9%, respectively. Accordingly, both Tyr-P of the head and ARC decreased from 68.4% to 10.2%, and from 65.7% to 14.6%, respectively. Asta pre-incubation prevented this drop and restored values of the percentage of ARC up to 40.8%. No alteration was found in either the ROS generation curve or sperm motility. In conclusion, Asta is able to preserve sperm by reducing the amount of HPV16-L1 bound onto membranes.


Asunto(s)
Reacción Acrosómica/efectos de los fármacos , Proteínas de la Cápside/metabolismo , Papillomavirus Humano 16/patogenicidad , Proteínas Oncogénicas Virales/metabolismo , Espermatozoides/efectos de los fármacos , Membrana Celular/efectos de los fármacos , Membrana Celular/metabolismo , Membrana Celular/virología , Chlorophyceae/química , Evaluación Preclínica de Medicamentos , Humanos , Masculino , Infecciones por Papillomavirus/prevención & control , Infecciones por Papillomavirus/virología , Unión Proteica/efectos de los fármacos , Especies Reactivas de Oxígeno , Capacitación Espermática/efectos de los fármacos , Motilidad Espermática/efectos de los fármacos , Espermatozoides/virología , Xantófilas/farmacología , Xantófilas/uso terapéutico
16.
Fertil Steril ; 110(4): 687-702.e2, 2018 09.
Artículo en Inglés | MEDLINE | ID: mdl-30196966

RESUMEN

OBJECTIVE: To investigate endometrial scratch injury (ESI) as an intervention to improve IVF outcome in women with a history of ET failure. DESIGN: Systematic review and meta-analysis. SETTING: Not applicable. PATIENT(S): Infertile women undergoing IVF after one or more failed ET. INTERVENTION(S): We included all randomized controlled trials of women undergoing IVF after one or more failed ET, where the intervention group received ESI and controls received placebo or no intervention. Pooled results were expressed as relative risk (RR) with a 95% confidence interval (95% CI). The review protocol was registered in PROSPERO before starting the data extraction (CRD42017082777). MAIN OUTCOME MEASURE(S): Live birth rate (LBR), clinical pregnancy rate (PR), multiple PR, miscarriage rate, ectopic pregnancy (EP) PR. RESULT(S): Ten studies were included (1,468 participants). The intervention group showed higher LBR (RR 1.38, 95% CI 1.05-1.80) and clinical PR (RR 1.34, 95% CI 1.07-1.67) in comparison to controls, without difference in terms of multiple PR, miscarriage rate, and EP PR. Double luteal ESI with pipelle was associated with the greatest effect on LBR (RR 1.54, 95% CI 1.10-2.16) and clinical PR (RR 1.30, 95% CI 1.03-1.65). The ESI was beneficial for patients with two or more previous ET failure, but not for women with a single previous failed ET. No effect was found in women undergoing frozen-thawed ET cycles. CONCLUSION(S): The ESI may improve IVF success in patients with two or more previous ET failures undergoing fresh ET. The ESI timing and technique seem to play a crucial role in determining its effect on embryo implantation.


Asunto(s)
Transferencia de Embrión/métodos , Endometrio/lesiones , Endometrio/fisiología , Infertilidad Femenina/terapia , Tasa de Natalidad/tendencias , Transferencia de Embrión/tendencias , Femenino , Humanos , Infertilidad Femenina/diagnóstico , Infertilidad Femenina/fisiopatología , Embarazo , Ensayos Clínicos Controlados Aleatorios como Asunto , Insuficiencia del Tratamiento
17.
Fertil Steril ; 110(1): 103-112.e1, 2018 07 01.
Artículo en Inglés | MEDLINE | ID: mdl-29908776

RESUMEN

OBJECTIVE: To evaluate the impact of antibiotic therapy for chronic endometritis (CE) on IVF outcome. DESIGN: Systematic review and meta-analysis. SETTING: Not applicable. PATIENT(S): Infertile women with history of recurrent implantation failure, defined as two or more failed ETs, undergoing one or more IVF cycle(s). INTERVENTION(S): The review was registered in PROSPERO (CRD42017062494) before the start of the literature search. Observational studies were identified by searching electronic databases. The following comparators were included: women with CE receiving antibiotics vs. untreated controls; women with cured CE vs. women with persistent CE; and women with cured CE vs. women with normal endometrial histology (negative for CE). The summary measures were reported as odds ratio (OR) with 95% confidence interval (CI). MAIN OUTCOME MEASURE(S): Clinical pregnancy rate (CPR), ongoing pregnancy rate/live birth rate (OPR/LBR), implantation rate (IR), miscarriage rate. RESULT(S): A total of 796 patients (from five studies) were included. Women receiving antibiotic therapy (without the histologic confirmation of CE cure) did not show any advantage in comparison with untreated controls (OPR/LBR, CPR, and IR). Patients with cured CE showed higher OPR/LBR (OR 6.81), CPR (OR 4.02), and IR (OR 3.24) in comparison with patients with persistent CE. In vitro fertilization outcome was comparable between women with cured CE and those without CE (OPR/LBR, CPR, and IR). Miscarriage rate was not significantly different between groups. CONCLUSION(S): Chronic endometritis therapy may improve IVF outcome in patients suffering from recurrent implantation failure. A control biopsy should always confirm CE resolution before proceeding with IVF.


Asunto(s)
Aborto Habitual/epidemiología , Aborto Habitual/terapia , Endometritis/epidemiología , Endometritis/terapia , Fertilización In Vitro , Infertilidad Femenina , Resultado del Embarazo , Aborto Habitual/etiología , Enfermedad Crónica , Implantación del Embrión/fisiología , Endometritis/complicaciones , Femenino , Fertilización In Vitro/métodos , Fertilización In Vitro/estadística & datos numéricos , Humanos , Infertilidad Femenina/epidemiología , Infertilidad Femenina/etiología , Infertilidad Femenina/terapia , Embarazo , Resultado del Embarazo/epidemiología , Índice de Embarazo , Recurrencia , Resultado del Tratamiento
19.
Gynecol Endocrinol ; 34(3): 233-237, 2018 Mar.
Artículo en Inglés | MEDLINE | ID: mdl-29037103

RESUMEN

Polycystic ovary syndrome (PCOS)is a gynecological endocrine disorder which is associated with systemic inflammatory status inducing red blood cells (RBC) membrane alterations related to insulin resistance and testosterone levels which could be greatly improved by myo-inositol (MYO) uptake. In this study we aim to evaluate the effect of MYO in reducing oxidative-related alterations through in vitro study on PCOS RBC. Blood samples from two groups of volunteers, control group (CG, n = 12) and PCOS patient group (PG, n = 12), were analyzed for band 3 tyrosine phosphorylation (Tyr-P), high molecular weight aggregate (HMWA), IgG in RBC membranes, and glutathione (GSH) in cytosol, following O/N incubation in the presence or absence of MYO. PCOS RBC underwent oxidative stress as indicated by higher band 3 Tyr-P and HMWA and increased membrane bound autologous IgG. Twenty four hours (but not shorter time) MYO incubation, significantly improved both Tyr-P level and HMWA formation and concomitant membrane IgG binding. However, no relevant modification of GSH content was detected. PCOS RBC membranes are characterized by increased oxidized level and enhanced sensitivity to oxidative injuries leading to potential premature RBC removal. MYO treatment is effective in reducing oxidative related abnormalities in PCOS patients probably restoring the inositol phospholipid pools of the membranes.


Asunto(s)
Eritrocitos/efectos de los fármacos , Inositol/farmacología , Síndrome del Ovario Poliquístico/sangre , Adulto , Eritrocitos/metabolismo , Femenino , Glutatión/metabolismo , Humanos , Inmunoglobulina G/metabolismo , Fosforilación/efectos de los fármacos , Adulto Joven
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA